US Bancorp
HRTX icon

US Bancorp’s Heron Therapeutics HRTX Stock Holding History

US Bancorp’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-726
Closed -$1.6K – 4237
2025
Q1 		$1.6K Buy
+726
New +$1.41K ﹤0.01% 3920
2022
Q4 		– Sell
-4,204
Closed -$18K – 4200
2022
Q3 		$18K Buy
+4,204
New +$16.4K ﹤0.01% 3065
2021
Q2 		– Sell
-350
Closed -$6K – 4032
2021
Q1 		$6K Hold
350
– – ﹤0.01% 3449
2020
Q4 		$7K Buy
350
+67
+24% +$1.17K ﹤0.01% 3307
2020
Q3 		$4K Hold
283
– – ﹤0.01% 3356
2020
Q2 		$4K Sell
283
-217
-43% -$3.56K ﹤0.01% 3375
2020
Q1 		$6K Buy
500
+300
+150% +$5.64K ﹤0.01% 3187
2019
Q4 		$5K Hold
200
– – ﹤0.01% 3273
2019
Q3 		$4K Sell
200
-3,908
-95% -$71.9K ﹤0.01% 3284
2019
Q2 		$76K Buy
4,108
+1,769
+76% +$35.3K ﹤0.01% 2337
2019
Q1 		$57K Buy
+2,339
New +$61.2K ﹤0.01% 2434
2017
Q1 		– Sell
-41
Closed -$1K – 3583
2016
Q4 		$1K Buy
+41
New +$643 ﹤0.01% 3450

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

US Bancorp's HRTX Position: Q2 2025 in Review

US Bancorp sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 726 shares — an estimated $1.6K sold.

US Bancorp first reported a position in HRTX in Q4 2016 and held it in 12 quarters. The position peaked at $76K in Q2 2019. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • US Bancorp reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • US Bancorp sold 726 Heron Therapeutics shares in Q2 2025, an estimated $1.6K.
  • US Bancorp first reported a position in Heron Therapeutics in Q4 2016 and held it in 12 quarters.
  • US Bancorp's Heron Therapeutics position peaked at $76K in Q2 2019.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on US Bancorp's 13F filing for Q2 2025, filed 24 Jul 2025.